European (EU-SPMS) Interferon beta-1b in Secondary Progressive M, ;
North American (NA-SPMS) Interferon beta-1b in Secondary Progres, ;
- view fewer
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
A European (EU) and a North American (NA) placebo-controlled study with interferon beta-1b (IFNB-1b) in secondary progressive multiple sclerosis (SPMS) showed divergent results with regard to their primary outcome of sustained Expanded Disability Status Scale (EDSS) progression, while effects were similar on relapse and MRI-related endpoints. Reasons for this discrepancy were explored in the combined dataset.
|Title:||Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.|
|Keywords:||Adult, Brain, Disability Evaluation, Disease Progression, Female, Humans, Immunologic Factors, Interferon-beta, Magnetic Resonance Imaging, Male, Middle Aged, Multicenter Studies as Topic, Multiple Sclerosis, Chronic Progressive, Outcome Assessment (Health Care), Patient Selection, Randomized Controlled Trials as Topic, Recurrence, Retrospective Studies, Severity of Illness Index, Treatment Outcome|
|UCL classification:||UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Brain Sciences
Archive Staff Only